LO FRANCIS 4
4 · Adaptive Biotechnologies Corp · Filed Mar 13, 2026
Research Summary
AI-generated summary of this filing
Adaptive Biotechnologies (ADPT) Chief People Officer Lo Francis Sells 30,593 Shares
What Happened
Lo Francis, Chief People Officer of Adaptive Biotechnologies (ADPT), sold 30,593 shares on March 11, 2026. The weighted average sale price was $14.08 per share, producing gross proceeds of approximately $430,749. The filing reports the transaction as a sale (S) executed in the open market.
Key Details
- Transaction date: March 11, 2026; Form 4 filed March 13, 2026 (filed within the required reporting window).
- Price: weighted average $14.08; sales occurred at prices ranging from $13.81 to $14.38.
- Shares sold: 30,593; total reported proceeds ≈ $430,749.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnotes: (F1) Sale executed pursuant to a Rule 10b5‑1 trading plan adopted September 15, 2025. (F2) Price shown is a weighted average; filer can provide breakdown of number of shares sold at each price upon request.
Context
This was a routine insider sale conducted under a prearranged 10b5‑1 plan. Sales under such plans are typically scheduled in advance and do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases by insiders tend to carry more informational weight than routine sales, but tracking patterns of multiple insiders can still be useful.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-11$14.08/sh−30,593$430,749→ 291,374 total
- 2,500(indirect: By Spouse)
Common Stock
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
- [F2]The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.81 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.